Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
    • Subscribe
Advertisement

Article

January 24, 2022

Gut Microbiome Makeup May Help Predict Skin-Related Immunotherapy Side Effects in Patients With Gastric Cancer

Author(s):

Lindsay Fischer
Conference|ASCO Gastrointestinal Cancers Symposium

Patients with gastric cancer who present with certain bacteria in their gut were found to be more likely to experience skin-related side effects from Opdivo treatment, research showed.

The makeup of a patient’s gut microbiome may lend insight regarding their risk to skin-related side effects from gastric cancer treatment, according to findings recently presented at the 2022 ASCO Gastrointestinal Cancers Symposium.

The researchers found that when patients present with Arthrobacter – a type of bacteria – and fatty acid metabolism pathways in their gut microbiomes, they were more likely to experience skin-related side effects from treatment with single-agent Opdivo (nivolumab).

Specifically, the IL6R and NLRC5 genomic pathways are predictive of Opdivo-related skin toxicities in this patient population, while SEMA4D and NOTCH1 are predictive of diarrhea. Then, the DELIVER trial validated the correlation with Arthrobacter and fatty acid metabolism.

The PD-1 inhibitor Opdivo has become integrated as a standard of care for patients with previously treated gastric cancer and has demonstrated benefits in overall survival. Despite this, about 10% of patients who receive Opdivo experience immune-related side effects. Furthermore, although several studies have shown that there is a link between gut microbiome composition and immunotherapy efficacy, relatively little research has been designed to assess this relationship within the context of advanced gastric cancer.

“Our study demonstrated that Arthrobacter and the fatty acid metabolism pathway were identified for candidate markers to predict skin-related (side effects), so patients with high levels of the genus or pathway experienced skin toxicity more frequently,” lead presenter Dr. Yu Sunakawa, of the Department of Clinical Oncology at St. Marianna University School of Medicine in Japan, said in an interview with Oncology Nursing News®, a sister publication of CURE®. “In near future clinical practice, by measuring the host-related markers such as gut microbiome, or polymorphous, we hope to be able to predict immune related adverse events to provide immunotherapy to patients with cancer more safely.”

The observational, translational, DELIVER trial enrolled 501 patients with advanced gastric cancer who received Opdivo alone between March 2018 and August 2019. Researchers collected fecal and blood samples before treatment initiation.

There were two separate cohorts in this study: a training cohort and a validation cohort. The training cohort included 200 patients, 180 of whom presented with evaluable and clinical genomic data of the gut microbiome. In comparison, the validation cohort included 301 enrolled patients, 257 of which presented with genomic data that was evaluable.

The primary endpoint was to identify the relationship between Opdivo efficacy and genomic pathways in gut microbiomes; progressive disease was identified in accordance with RECIST criteria – a standard that measures how tumors respond to different cancer treatments. The secondary end point was to identify potentially predictive biomarkers within the gut microbiome, as well as their correspondent clinical outcomes.

A year following last patient enrollment, at a data cutoff date of August 2020, there were 87 confirmed cases of diarrhea, 44 skin eruptions, 29 hypothyroidism events and 11 adrenal disorders among participants in the safety population (487 patients).

“The … analysis indicated that there is significant association of genetic polymorphism of NOTCH1 and SEMA4D with diarrhea and NLR family domain containing 5 and interleukin-6 receptor gene (IL6R) with skin toxicity,” concluded Sunakawa.

He added that further analysis will be performed using updated clinical toxicity data soon.

This article was originally published on Oncology Nursing News as, “Gut Microbiome May Be Useful in Predicting Toxicities With Nivolumab in Advanced Gastric Cancer.”

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Enabling patients to generate CAR T-cells internally could cut kidney cancer therapy costs, explained Dr. Wayne Marasco of Dana-Farber Cancer Institute.
Kidney Cancer Research Embraces Biology-Driven Precision Approach
Image of man with text.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
Image of two doctors and text.
Imiage of two doctors with text.
Image of two doctors and text.
Image of patient and doctor.
Image of two doctors with text.
image of gerds
Related Content
Advertisement
PD-1 treatment may help by shifting certain immune cells to fight diseases like kidney cancer: © stock.adobe.com.
July 24th 2025

Key Immune Cells Linked to Better Kidney Cancer Outcomes

Ashley Chan
PD-1 treatment may help by shifting certain immune cells to fight diseases like kidney cancer; higher CD163-positive TAMs are linked to better outcomes.
FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment
February 5th 2024

FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment

Alex Biese Brielle Benyon
One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.
Data from the KEYNOTE-B61 trial show tumor shrinkage in different types of kidney cancer, including papillary and chromophobe subtypes: © stock.adobe.com.
July 22nd 2025

Clinical Trial Confirms Keytruda and Lenvima Benefit in Kidney Cancer

Russ Conroy
Data from the KEYNOTE-B61 trial show tumor shrinkage in different types of kidney cancer, including papillary and chromophobe subtypes.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
Image of kidney.
July 20th 2025

Welireg Improves Quality-Adjusted Survival Time in Advanced RCC

Russ Conroy
Welireg improved quality-adjusted survival time versus Afinitor in advanced renal cell carcinoma, extending progression-free survival and reducing side effects.
Researchers are exploring the use of CAR T-cell therapy in clear cell renal cell carcinoma, a type of kidney cancer: © stock.adobe.com.
July 20th 2025

Dual-Targeting CAR T Therapy Shows Potential in Advanced Kidney Cancer

Ashley Chan
Researchers are building on the success of CAR T therapy in blood cancers to explore its use in clear cell renal cell carcinoma, a type of kidney cancer.
Related Content
Advertisement
PD-1 treatment may help by shifting certain immune cells to fight diseases like kidney cancer: © stock.adobe.com.
July 24th 2025

Key Immune Cells Linked to Better Kidney Cancer Outcomes

Ashley Chan
PD-1 treatment may help by shifting certain immune cells to fight diseases like kidney cancer; higher CD163-positive TAMs are linked to better outcomes.
FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment
February 5th 2024

FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment

Alex Biese Brielle Benyon
One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.
Data from the KEYNOTE-B61 trial show tumor shrinkage in different types of kidney cancer, including papillary and chromophobe subtypes: © stock.adobe.com.
July 22nd 2025

Clinical Trial Confirms Keytruda and Lenvima Benefit in Kidney Cancer

Russ Conroy
Data from the KEYNOTE-B61 trial show tumor shrinkage in different types of kidney cancer, including papillary and chromophobe subtypes.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
Image of kidney.
July 20th 2025

Welireg Improves Quality-Adjusted Survival Time in Advanced RCC

Russ Conroy
Welireg improved quality-adjusted survival time versus Afinitor in advanced renal cell carcinoma, extending progression-free survival and reducing side effects.
Researchers are exploring the use of CAR T-cell therapy in clear cell renal cell carcinoma, a type of kidney cancer: © stock.adobe.com.
July 20th 2025

Dual-Targeting CAR T Therapy Shows Potential in Advanced Kidney Cancer

Ashley Chan
Researchers are building on the success of CAR T therapy in blood cancers to explore its use in clear cell renal cell carcinoma, a type of kidney cancer.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.